Marks DL - Search Results

1

Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.

DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, Inui A, Taylor JE, Halem HA, Dong JZ, Datta R, Culler MD, Marks DL. DeBoer MD, et al. Among authors: marks dl. Endocrinology. 2007 Jun;148(6):3004-12. doi: 10.1210/en.2007-0016. Epub 2007 Mar 8. Endocrinology. 2007. PMID: 17347304

2

The central melanocortin system can directly regulate serum insulin levels.

Fan W, Dinulescu DM, Butler AA, Zhou J, Marks DL, Cone RD. Fan W, et al. Among authors: marks dl. Endocrinology. 2000 Sep;141(9):3072-9. doi: 10.1210/endo.141.9.7665. Endocrinology. 2000. PMID: 10965876

3

Role of the central melanocortin system in cachexia.

Marks DL, Ling N, Cone RD. Marks DL, et al. Cancer Res. 2001 Feb 15;61(4):1432-8. Cancer Res. 2001. PMID: 11245447

4

Differential role of melanocortin receptor subtypes in cachexia.

Marks DL, Butler AA, Turner R, Brookhart G, Cone RD. Marks DL, et al. Endocrinology. 2003 Apr;144(4):1513-23. doi: 10.1210/en.2002-221099. Endocrinology. 2003. PMID: 12639936

5

Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease.

Mak RH, Cheung W, Cone RD, Marks DL. Mak RH, et al. Among authors: marks dl. Pediatr Nephrol. 2005 Mar;20(3):427-31. doi: 10.1007/s00467-004-1789-1. Epub 2005 Jan 21. Pediatr Nephrol. 2005. PMID: 15662537 Review.

6

The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.

Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, Fleck BA, Brown BT, Marks DL. Markison S, et al. Among authors: marks dl. Endocrinology. 2005 Jun;146(6):2766-73. doi: 10.1210/en.2005-0142. Epub 2005 Mar 17. Endocrinology. 2005. PMID: 15774557

7

Role of leptin and melanocortin signaling in uremia-associated cachexia.

Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Cheung W, et al. Among authors: marks dl. J Clin Invest. 2005 Jun;115(6):1659-65. doi: 10.1172/JCI22521. J Clin Invest. 2005. PMID: 15931394 Free PMC article.

8

The use of melanocortin antagonists in cachexia of chronic disease.

Scarlett JM, Marks DL. Scarlett JM, et al. Among authors: marks dl. Expert Opin Investig Drugs. 2005 Oct;14(10):1233-9. doi: 10.1517/13543784.14.10.1233. Expert Opin Investig Drugs. 2005. PMID: 16185165 Review.

9

Cachexia: lessons from melanocortin antagonism.

Deboer MD, Marks DL. Deboer MD, et al. Among authors: marks dl. Trends Endocrinol Metab. 2006 Jul;17(5):199-204. doi: 10.1016/j.tem.2006.05.005. Epub 2006 Jun 5. Trends Endocrinol Metab. 2006. PMID: 16750633 Review.

10

Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.

DeBoer MD, Marks DL. DeBoer MD, et al. Among authors: marks dl. Nat Clin Pract Endocrinol Metab. 2006 Aug;2(8):459-66. doi: 10.1038/ncpendmet0221. Nat Clin Pract Endocrinol Metab. 2006. PMID: 16932335 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

308 results

Search Page

Filters